156 related articles for article (PubMed ID: 36971773)
1. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma.
Kelly CM; Qin LX; Whiting KA; Richards AL; Avutu V; Chan JE; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Adamson T; Singer S; Bartlett EK; Crago AM; Yoon SS; Hwang S; Erinjeri JP; Antonescu CR; Tap WD; D'Angelo SP
Clin Cancer Res; 2023 Jun; 29(11):2043-2051. PubMed ID: 36971773
[TBL] [Abstract][Full Text] [Related]
2. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
3. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
5. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Powderly JD; Klempner SJ; Naing A; Bendell J; Garrido-Laguna I; Catenacci DVT; Taylor MH; Lee JJ; Zheng F; Zhou F; Gong X; Gowda H; Beatty GL
Oncologist; 2022 Nov; 27(11):905-e848. PubMed ID: 36156099
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract][Full Text] [Related]
7. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Mitchell TC; Hamid O; Smith DC; Bauer TM; Wasser JS; Olszanski AJ; Luke JJ; Balmanoukian AS; Schmidt EV; Zhao Y; Gong X; Maleski J; Leopold L; Gajewski TF
J Clin Oncol; 2018 Nov; 36(32):3223-3230. PubMed ID: 30265610
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Tian Z; Dong S; Yang Y; Gao S; Yang Y; Yang J; Zhang P; Wang X; Yao W
BMC Cancer; 2022 Jan; 22(1):56. PubMed ID: 35022029
[TBL] [Abstract][Full Text] [Related]
9. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Hellmann MD; Gettinger S; Chow LQM; Gordon M; Awad MM; Cha E; Gong X; Zhou G; Walker C; Leopold L; Heist RS
Int J Cancer; 2020 Oct; 147(7):1963-1969. PubMed ID: 32141617
[TBL] [Abstract][Full Text] [Related]
11. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
12. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pollack SM; Redman MW; Baker KK; Wagner MJ; Schroeder BA; Loggers ET; Trieselmann K; Copeland VC; Zhang S; Black G; McDonnell S; Gregory J; Johnson R; Moore R; Jones RL; Cranmer LD
JAMA Oncol; 2020 Nov; 6(11):1778-1782. PubMed ID: 32910151
[TBL] [Abstract][Full Text] [Related]
13. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Doi T; Fujiwara Y; Shitara K; Shimizu T; Yonemori K; Matsubara N; Ohno I; Kogawa T; Naito Y; Leopold L; Munteanu M; Yatsuzuka N; Han SR; Samkari A; Yamamoto N
Invest New Drugs; 2021 Feb; 39(1):152-162. PubMed ID: 32564277
[TBL] [Abstract][Full Text] [Related]
14. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
18. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
Gibney GT; Hamid O; Lutzky J; Olszanski AJ; Mitchell TC; Gajewski TF; Chmielowski B; Hanks BA; Zhao Y; Newton RC; Maleski J; Leopold L; Weber JS
J Immunother Cancer; 2019 Mar; 7(1):80. PubMed ID: 30894212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
